This shows potential for Ozempic and other GLP1 receptor agonists as potential longevity drugs beyond their role as diabetes and obesity medication, and warrants more credibility to earlier claims that focused only on obese patients. Ref (5)

Ozempic had better Alzheimer's disease protective advantage in women, and in the special case of SGLT2-inhibitors, the Ozempic advantage was exclusive in women, with SGLT2 inhibitors outperforming Ozempic slightly by 14% in Alzheimer's disease.

This is very intriguing in light…

While Ozempic also bestowed 47% relative risk reduction to women, other GLP-1 receptor agonists slightly outperformed Ozempic in men (14% relative Alzheimer's disease risk).

The study compared Semaglutide (Commercially: Ozempic for diabetes, Wegovy for weight-loss) against 7 other type 2 diabetes medications for its ability to prevent Alzheimer's disease in older type 2 diabetes patients, a critical group with 65% higher risk for developing…

Ozempic outperformed every other type 2 diabetes medication in preventing Alzheimer's disease, with a 78% and 52% risk reduction compared to insulin, in women and men, respectively.

Ozempic surpasses all other diabetes medications in preventing Alzheimer's disease in diabetics >60 years, effect is more pronounced in women, and independent of obesity.

A recently published article in Alzheimer & Dementia (1) reported 7 target trial emulations (a highly standardized type of retrospective observational studies) analyzing the data of over 1 million type 2 diabetes patients over 60 (over 116 million Electronic Health Records EHRs…

@elonmusk @neuralink Agreed, a great application for the tech

In Miami this week with heretics and health nuts. What if they had a baby?

Pretty soon, we’ll find out that thinking without the aid of AI will feel rather limiting.